NewAmsterdam Pharma (NAMS) Retained Earnings (2021 - 2026)

NewAmsterdam Pharma has reported Retained Earnings for 6 years, with the latest figure at -$810.8 million in Q1 2026.

• Quarterly Retained Earnings fell 35.57% year-over-year to -$810.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$810.8 million (down 35.57% YoY) and the FY2025 annual result came in at -$762.4 million, down 36.49% from the prior year.
• Retained Earnings fell to -$810.8 million in Q1 2026 per NAMS's latest filing, from -$762.4 million in the prior quarter.
• Over five years, Retained Earnings peaked at -$121.8 million in Q4 2022 and troughed at -$810.8 million in Q1 2026.
• A 5-year average of -$500.9 million and a median of -$512.5 million in 2024 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2026: Retained Earnings sank 206.99% in 2022, then sank 35.57% in 2026.
• Over 5 years, Retained Earnings stood at -$121.8 million in 2022, then tumbled by 160.29% to -$317.0 million in 2023, then plunged by 76.22% to -$558.6 million in 2024, then slumped by 36.49% to -$762.4 million in 2025, then slipped by 6.35% to -$810.8 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$810.8 million, -$762.4 million, and -$687.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.